MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Fiche publication
Date publication
janvier 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr LEPAGE Côme
Tous les auteurs :
Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V
Lien Pubmed
Résumé
Chemo-radiotherapy (CRT) is the standard treatment for non-metastatic anal squamous cell carcinomas (ASCC). Despite excellent results for T1-2 stages, relapses still occur in around 35% of locally advanced tumors. Recent strategies focus on treatment intensification, but could benefit from a better patient selection. Our goal was to assess the prognostic value of pre-therapeutic MRI radiomics on 2-year disease control (DC).
Mots clés
anal cancer, machine learning, magnetic resonance imaging, precision medicine, prediction medicine, radiomics
Référence
Cancers (Basel). 2021 Jan 7;13(2):